A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

NCT00192634 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

357

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Emtricitabine 200mg - Tenofovir 300mg
DRUG: Abacavir 600mg - Lamivudine 300mg

Sponsor

Kirby Institute